Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Biomarkers, Tumor
/ blood
Carcinoma, Ovarian Epithelial
/ blood
Case-Control Studies
Creatinine
/ blood
Female
Humans
Middle Aged
Neoplasms
/ blood
Ovarian Neoplasms
/ blood
Poland
Postmenopause
/ blood
Pregnancy
Premenopause
/ blood
Reference Values
Risk Factors
Smoking
/ physiopathology
WAP Four-Disulfide Core Domain Protein 2
/ metabolism
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
02
2019
revised:
14
05
2019
accepted:
16
07
2019
entrez:
5
10
2019
pubmed:
5
10
2019
medline:
23
2
2020
Statut:
epublish
Résumé
Defining precisely the normal range of HE4 protein is crucial for the proper interpretation of tumor marker results and for a more efficient diagnosis of ovarian malignancy. The aim of our study was to evaluate a reference limit of HE4 protein in a population to promote and facilitate the common use of HE4 protein assays. We also tried to identify potential association of HE4 levels with other conditions such as smoking, age, BMI, and creatinine levels. Blood samples were collected from 617 patients divided into three groups: healthy, pregnant, and with benign ovarian tumors. Serum HE4 concentrations were measured following a standard procedure. HE4 reference ranges for each group and association of HE4 levels with BMI, creatinine, and smoking were investigated. HE4 reference limit for healthy patients equals 85 pmol/l, which becomes 73 pmol/l and 93 pmol/l for pre and postmenopausal subgroups, respectively. There is a statistically significant correlation between HE4 serum level and smoking ( HE4 protein value strongly depends on the patient's age and smoking. The serum concentration of HE4 marker increases with the duration of pregnancy. Understanding the normal range of HE4 protein enables the correct interpretation of marker measurements. This may result in an earlier and more effective diagnosis of ovarian cancer.
Identifiants
pubmed: 31583027
doi: 10.1155/2019/3890906
pmc: PMC6754914
doi:
Substances chimiques
Biomarkers, Tumor
0
WAP Four-Disulfide Core Domain Protein 2
0
WFDC2 protein, human
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3890906Informations de copyright
Copyright © 2019 Emilia Gasiorowska et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
J Ovarian Res. 2015 Nov 09;8:72
pubmed: 26552478
Eur J Gynaecol Oncol. 2015;36(4):406-9
pubmed: 26390692
J Card Fail. 2017 Jan;23(1):12-19
pubmed: 27224553
Acta Obstet Gynecol Scand. 2014 Jul;93(7):640-6
pubmed: 24734893
Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8
pubmed: 22284961
Tumour Biol. 2012 Feb;33(1):141-8
pubmed: 22105734
J Clin Lab Anal. 2018 Jun;32(5):e22368
pubmed: 29194801
Respir Res. 2006 Apr 06;7:61
pubmed: 16600032
Ann Clin Biochem. 2012 Jul;49(Pt 4):377-80
pubmed: 22688735
Anticancer Res. 2010 Nov;30(11):4779-83
pubmed: 21115941
J Obstet Gynaecol Res. 2018 Nov;44(11):2053-2058
pubmed: 30125422
Genet Mol Res. 2015 Mar 27;14(1):2156-61
pubmed: 25867363
Obstet Gynecol. 2011 Aug;118(2 Pt 1):280-8
pubmed: 21775843
Hum Pathol. 2013 May;44(5):734-42
pubmed: 23084584
Tumour Biol. 2011 Dec;32(6):1087-95
pubmed: 21863264
J Reprod Immunol. 2015 Nov;112:58-62
pubmed: 26232150
Am J Obstet Gynecol. 2012 Apr;206(4):349.e1-7
pubmed: 22301440
Gynecol Oncol. 2015 Sep;138(3):640-6
pubmed: 26086566
Clin Chim Acta. 2015 Jan 1;438:35-42
pubmed: 25127713